Brief: Kronos Bio Announces Positive Data From Ongoing Phase 1/2 Trial Of Oral CDK9 Inhibitor KB-0742
29/11/2021 12:18
Nov 29 (Reuters) - Kronos Bio Inc KRON.O :
* KRONOS BIO ANNOUNCES POSITIVE DATA FROM ONGOING PHASE 1/2
TRIAL
OF ORAL CDK9 INHIBITOR KB-0742
* KRONOS BIO INC - INITIAL DATA DEMONSTRATE LONG PLASMA
HALF-LIFE
AND DOSE-DEPENDENT TARGET INHIBITION
* KRONOS BIO INC - TRIAL IS CONTINUING TO ENROLL PATIENTS ON
THREE-DAY ON, FOUR-DAY OFF SCHEDULE
Source text for Eikon: ID:nGNX1pCY1h
Further company coverage: KRON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kronos Bio
See all newsBrief: Kronos Bio Inc - Terminates Office Lease At 301 Binney Street - SEC Filing
Brief: Kronos Bio Inc - Enters Transition Agreement With Genentech
U.S. STOCKS ON THE MOVE - Ambarella, Dell, Nordstrom
U.S. STOCKS ON THE MOVE - Golden Ocean, Guess, Symbotic
U.S. STOCKS ON THE MOVE-HP, Urban Outfitters, 3D Systems